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Feasibility of simultaneous pre- and postfilter
transcranial Doppler monitoring during
carotid artery stenting
Zsolt F. Garami, MD, Jean Bismuth, MD, Kristofer M. Charlton-Ouw, MD,
Mark G. Davies, MD, PhD, MBA, Eric K. Peden, MD, and Alan B. Lumsden, MD, Houston, Tex
Objective: Carotid artery stenting (CAS) is emerging as an acceptable treatment alternative to surgery for patients with
carotid artery stenosis. The major risk of CAS is cerebral embolization of plaque and thrombus causing stroke or
asymptomatic brain infarction. Use of embolic protection devices (EPD) to trap emboli before they reach the brain is now
standard practice in CAS. The pore size of the currently available filters is>100microns and emboli smaller than the EPD
pores can still reach the brain. While the use of EPD is widespread, little evidence exists of their in vivo efficacy in
preventing distal embolization. Our aimwas to quantify the number of emboli reaching the brain with the device in place.
Therefore, the expected value of this report is in its description of a novel application of transcranial Doppler (TCD). Due
to the limited number of cases, it is not intended to support the use of one EPD over another.
Methods: Six patients were monitored with ipsilateral simultaneous dual probe TCD during CAS. Two types of cerebral
protection systems were evaluated: FilterWire EZ System (FW; Boston Scientific, Santa Clara, Calif) and GORE Neuro
Protection System (NPS; W.L. Gore and Associates, Flagstaff, Ariz). By placing TCD probes both proximal and distal to
the filterwire EPD, we quantified the microembolic signals before the EPD as well as those, which reached the intracranial
circulation after the EPD. One probe was placed submandibularly to monitor the ICA (SICA), while another was placed
transtemporally to monitor the middle and anterior cerebral artery (MCA  ACA). We compare the number of
extracranial emboli prior to the EPD with the number of intracranial emboli after the EPD.
Results: Dual probe monitoring was successful during the five stages of the CAS: lesion crossing (LC), predilatation
(PreD), stent placement (SP), postdilatation (PostD), and filter/device removal (FR/DR). Using FW during LC by
probe 1 (SICA)/probe 2 (MCA  ACA): (18 [range, 15-22]/15 [range, 11-20] ), PreD (111 [range, 101-121]/
101 [range, 90-111] ), SP (68 [range, 60-76]/42 [range, 30-53] ), PostD (27 [range, 25-30]/24 [range, 22-27]),
FR (0.3 [range, 0-1]/0.7 [range, 0-1]) average number of microembolic signals were detected. Using NPS during
LC (1.7 [range, 0-3]/1 [range, 0-2]), PreD (0/1.7 [range, 0-4]), SP (0/0), PostD (0/0), DR (18 [range,
0-18]/6.7 [range, 1-13]) average number of microembolic signals were detected.
Conclusion: EPD significantly reduces but does not eliminate the number of microemboli reaching the brain during
carotid artery angioplasty and stenting. We propose monitoring of CAS with submandibular and transtemporal
TCD probes to further evaluate the practice of distal embolization protection. Although our study is not powered
to make any recommendations about EPDs, we believe that sequential dual probe TCD monitoring is a worthy tool
with the potential to give vital information to assess the various devices and the techniques of utilization. ( J Vasc
Surg 2009;49:340-5.)Carotid endarterectomy (CEA) is a procedure that
has withstood the test of time. It has been performed
with great success and safety over approximately 50
years, supported by multiple multicenter randomized
trials.1,2 Carotid artery stenting (CAS) has now been
performed for nearly 10 years, with the addition of
embolic protection devices (EPD) since the year 2000.
Gray et al showed that the predictors of poor outcome,
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340by multivariate analysis, were predilatation without
EPD, symptomatic carotid lesions, age, and the use of
multiple stents per procedure.3 It was also noted by
transcranial Doppler (TCD) that showers of microem-
boli noted during postdilatation have a significant asso-
ciation with adverse cerebral outcome.4
The benefits of using EPDs seem evident. In the case of
filters, their design has to be such that it not only allows
adequate cerebral perfusion, but that its pore size is appro-
priate to prevent major embolization. Evidence has shown
that deployment of a filter device reduces cerebral blood
flow by 10% to 30%.5 Pore size for the available EPDs varies
from 110 m to 150 m, but has generally been shown to
be able to eliminate up to 96% of embolic particles.6
Protection with carotid flow reversal has also been shown to
produce a remarkably low incidence of intraprocedural
cerebral embolization.7,8 Despite this fact, several studies
have shown that new intracranial lesions are detected by
magnetic resonance (MR) diffusion-weighted imaging
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DWI detected new focal ischemic lesions in 40% of pa-
tients.12 It is our goal to describe maneuvers during CAS,
which prompt embolization, as well as determining by
TCD sequential dual probe monitoring, the ability of the
EPD to prevent emboli from reaching the cerebral circula-
tion. The use of EPDs is almost universally applied during
CAS procedures and so this approach to dual monitoring
during the procedure should be a successful way of describ-
ing the performance measures of EPDs.
The value of this report is in its description of a novel
application of TCD. Due to the limited number of cases, it is
not intended to support the use of one EPD over another.
PATIENTS AND METHODS
The six patients included in this analysis were evaluated
and treated in the period between May 2007 and February
2008. These were consecutive patients on whom sequential
dual probe TCD technique was used. They all met criteria for
being poor surgical candidates to have a carotid endarterecto-
my.13 Comorbidities were recorded. All procedures were per-
formed by a single experienced vascular surgeon (A.B.L.).
TCD monitoring protocol and interpretation
Probe/head frame placement. A commercially avail-
able probe-holding head frame system (Marc 600 series;
Spencer Technologies, Seattle,Wash) is used to affix probes
just anterior to the ear at the posterior temporal bone
windows and second probe was placed for submandibular
insonation at the angle of jaw (Fig 1).14
TCD machine and software settings. Doppler pa-
rameters for our PMD100 (Spencer Technologies, Seattle,
Wash) are: transducer  2 MHz, 13 mm circular probe
surface; pulse repetition frequency  8 kHz; fast Fourier
transformation  128 points, overlap  66%; sample vol-
ume axial length  9 mm; output power  80% to 100%
(700 mW/cm2 spatial peak temporal average intensity);
filter  125-175 Hz; noise 0-3 dB; range 30 dB; Doppler
volume4dB;M-mode range30dB; and sweep period
4-16 seconds.
We identified the proximal middle cerebral artery
(MCA) and anterior cerebral artery (ACA), as well as the
submandibular internal carotid artery (SICA) before the
start of the procedure and selected the appropriate gate for
spectral display. The M-mode screen enables visualization
of intracranial flow signals from depths of between 25 and
85 mm from the ultrasound probe (Fig 2, online only),
making it easier for the sonographer to localize the blood
flow in the target vessel.
The spectral waveform above the zero line represents
the MCA flow, traveling towards the probe, and corre-
sponds with the red-labeled signal on the PMD display.
The spectral waveform below the zero line represents ACA
flow, traveling away from the probe and is displayed by a
blue-labeled signal on the PMD. PMD-TCD signal was
continuously recorded, while postprocedural analysis of the
recording was completed for quantification of microem-
bolic signals (MES).Microembolus signal detection. The intensity of the
Doppler signal for an embolus traveling in blood depends
on the size and acoustic impedance. Air has much lower
acoustic impedance than blood and, therefore, reflects
sound waves to a greater extent.
Based on Consensus Committee guidelines, certain
technical criteria must be met to qualify as microembolic
signals (MES) by TCD.15
A microembolic signal recorded on the PMD screen
can be tracked as it moves through the intracerebral circu-
lation (Fig 3, online only). An embolus traveling up the
middle cerebral artery (MCA) would first appear in the
proximal portion of the artery on PMD at 60-mm and then
travels distally in the MCA at 40-mm. MCA embolic signal
has a slight tilt or forward slash-shaped signal (“/”) in
PMD that indicates direction. An ACA or SICA MES
signature on PMD screen has a backslash-shaped signal
(“\”). Calculating the MCA and ACA total MES count on
the PMD screen permits direct comparison between the
two TCD probes because almost all the ICA flow volume/
MES would be delivered into these arteries.
Extraneous activity such as muscle movement, skin
scrubbing, cough or tap against the head frame, and electric
artifacts appears at various depths on PMD at the same time
and removed from the PMD display and would not be
counted by the automatic embolus detection.
Air emboli during contrast injection were not included in
our analysis. The emboli counting was performedwithout the
use of the automatic emboli detection software. To evaluate
the embolic potential of the various steps of the procedure, we
divided it into five parts: lesion crossing, predilatation, stent
placement, postdilatation, and filter/device removal. The
MES counts from the PMD screen were entered into the
database for respective parts of the procedure.
Carotid artery stenting
Extracranial and intracranial angiography was per-
Fig 1. Dual probe transcranial Doppler monitor setup as seen on
the patient and as it relates to the carotid artery embolic protection
device.formed bilaterally at the time of the intervention to confirm
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cedure.We never compromised our visualization due to the
TCD probes. An optimal view allowing proper identifica-
tion of the culprit lesion and the filter was always assured
prior to proceeding. Once the severity of the lesion had
been verified and the anatomy deemed to be suitable for
CAS, the procedure was performed. The CAS technique
involved use of either FilterWire EZ System (Boston Scien-
tific, Santa Clara, Calif) or GORENeuro Protection System
(W.L. Gore and Associates, Flagstaff, Ariz), a reversal of
flow mechanism. After placement of the wire and EPD in
the appropriate vessel, as per standard CAS technique,
predilatation with a 3.0-5.0-mm balloon was performed.
The preferred stent in all cases treated in this series of
patients was the NexStent Carotid Stent (Boston Scientific,
Santa Clara, Calif). This stent has a closed stent configura-
tion, with self-sizing capability so that tapered and non-
tapered vessels can be treated. Stent deployment was fol-
lowed by postdilatation in all cases. Technical success was
considered to be a residual stenosis in the stented arterial
segment of30%. Postprocedural intracranial angiography
was also performed.
All patients were given bivalirudin, as per standard
protocol, after having gained secure access via the femoral
artery, which consisted of a bolus dose of 0.75 mg/kg
followed by a constant infusion of 1.75 mg/kg/hr for the
duration of the procedure. Activated clotting times were
followed and all remained in the therapeutic range thereby
not requiring additional boluses. Patients who had no
contraindication were given both aspirin 81 mg and Plavix
75 mg postoperatively.
RESULTS
A total of 6 patients were interrogated using dual probe
TCD monitoring during CAS. Three of these had cerebral
embolic protection with the FilterWire EZ System (FW),
while the other three with the GORE Neuro Protection
System (NPS). Procedural success was 100% for CAS as it
was for dual probe TCD monitoring. Only one stent was
used for each of the cases. No patient suffered a periproce-
dural neurological event, defined as a period from initiation
of procedure to a 2-week follow-up.
Dual probe monitoring was successful during the five
stages of the CAS: lesion crossing (LC), predilatation
(PreD), stent placement (SP), postdilatation (PostD), and
filter/device removal (FR/DR). Using FW during LC by
probe 1 (SICA)/probe 2 (MCA  ACA): (18 [range, 15-
22]/15 [range, 11-20]), PreD (111 [101-121]/101[range,
90-111]), SP (68 [range, 60-76]/42 [range, 30-53]), PostD
(27 [range, 25-30]/24 [range, 22-27]), and FR (0.3
[range, 0-1]/0.7 [range, 0-1]), average number of micro-
embolic signals were detected. Using NPS during LC (1.7
[range, 0-3]/1 [range, 0-2]), PreD (0/1.7 [range, 0-4]),
SP (0/0), PostD (0/0), and DR (18 [range, 0-18]/6.7
[range, 1-13]), average number of microembolic signals
were detected.
The median age of the patients was 72 years. Five of
6 (83%) patients had hypertension and coronary arterydisease, all patients had a history of hyperlipidemia, 4 of
6 (67%) had a history of tobacco use, while only 2
patients were diabetic. Of the 6 patients, three were for
symptomatic cerebrovascular disease. All were on anti-
platelet therapy except one who was intolerant of aspirin
and clopidogrel.
Embolic signals identified during contrast injection
were easily identifiable and were excluded from the final
embolic counts (Fig 4, online only). Emboli detected at the
level of the ICA, which also traveled into the MCA were
observed to do so after a one to two heart beat delay (Fig 5,
online only). Interestingly, in 1 patient, an embolus was
identified in the SICA and traveled into the ACA and, on
the same 8-second screen, a second SICA embolus instead
traveled into the MCA (Fig 3, online only).
As we had expected, the only MES noted on TCD
when using the reversal of flow system, were found to occur
after and during removal of the (Fig 6) NPS. For the
patients with the FilterWire EZ System, the results were
very different (Fig 7). The greatest number of emboli were
seen during predilatation (Fig 8), where an average of 111
emboli were seen at the level of the SICA, and 101 in the
MCA. This accounts for a filter capture rate of 9% during
this segment of the procedure. During stent deployment, a
significant number of emboli were appreciated at the level
of the SICA with 38% being captured by the filter and
therefore not reaching theMCA. Overall 20% fewer emboli
were identified at the level of the MCA, relative to the
SICA.
Eight total emboli were detected during the procedure
at the level of the MCA with flow reversal vs 547 with the
distal filter device. During device removal, the trend was
reversed so that 20 emboli were seen for reversal of flow and
only two with the filter device. Therefore, removal of the
device accounted for 71% of all emboli measured in the
MCA with the reversal of flow system.
DISCUSSION
The treatment of carotid stenosis has the goal of pre-
venting embolic events, but treating the culprit lesion itself
carries a risk of embolization. The evolution of the man-
agement of carotid artery disease has meant that CAS is
now a formidable counterpart to CEA. One of the major
developments in CAS has been the creation of EPDs.
Rosenkranz et al showed that most cerebral microemboli
that occur during CAS are gaseous, while only 15% of
microemboli are actually solid. Interestingly, they noted no
relationship between the number of solid emboli and new
ischemic lesions as detected by MR DWI.16 On the other
hand, it has previously been shown that particulate matter
visible to the naked eye can be found in EPDs after CAS in
19% to 63% of cases.17-19
Furthermore, microscopic analysis revealed that 50%
to 80% of EPDs contain debris. Coggia et al showed that
most emboli originating from carotid bifurcations dur-
ing balloon angioplasty were actually less than 60 m.20
These emboli would therefore have the potential of
traversing the pores of the filter devices. By dual TCD
) defl
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 2 Garami et al 343monitoring, we were able to identify embolic signals in
the ICA proximal to the filter as well as distal to the filter
in the MCA. Overall, only 20% of the emboli detected in
the submandibular position were not identified by the
temporal TCD probe, and therefore the presumption is
that the remainder of the particles are ending up in the
cerebral circulation.
Although, TCD remains the only method to detect
cerebral embolization, and this has been well documented
for both CEA and CAS, not all of the MES seen on
M-mode will be represented and detected on the spectral
screen. Spencer et al reported 40% higher MES count on
M-mode vs single channel TCD with spectral screen
Fig 6. Using the GORE Neuro Protection System (W.L
signals (MES) were identified during stent placement (B
Fig 7. Graphic display of average microemboli count during
stenting with filter protection (A) and GORE Neuro Protection
System (W.L. Gore and Associates, Flagstaff, Ariz) (B).only.21 One of the limitations of TCD remains its oper-ator/interpretation dependence as well as the occasional
suboptimal temporal bone windows, reportedly an issue
in approximately 16% of cases.4 Additionally, an ultra-
sound signal tested by using dual frequency TCD probes
is unable to characterize the consistency of the embolus.
Differentiating gas from particulate matter with a high
level of sensitivity has been reported and would help
determine the embolic source. The minimum detectable
diameter of gaseous emboli has been reported at 10
microns while particulate emboli can be detected from
40 microns.22 Again then, pore size becomes vital to
cerebral protection as pore size determines which emboli
have the ability to travel to MCA from the working areas.
The major limitation of filter pore size is that decreasing
the pore size also decreases flow.
The greatest number of emboli identified in our series
was during the predilatation phase of the CAS procedure,
which is not consistent with a great deal of the literature
which has identified stent deployment as the most “em-
bologenic” aspect of CAS.16,23,24 There is inconsistency in
the actual effects of microemboli , with showers of micro-
emboli at postdilatation being strongly associated with
adverse cerebral outcome.4 We have no explanation for the
preponderance of emboli during predilatation, but this step
is not one that is uniformly practiced by all practitioners of
CAS and this may be an area that requires further evalua-
tion.
The major achievement of this report is to identify a
novel way of using dual level TCD monitoring to evaluate
EPDs. It has been described that a significant number of
emboli are identified in vascular territories independent of
the stented ICA,6 which can be monitored using additional
TCD systems.
In conclusion, our approach to CAS monitoring has
identified a useful way to evaluate EPDs, but the analysis is
limited in number and therefore is unlikely to modify
re and Associates, Flagstaff, Ariz), (A) no microembolic
ation of carotid balloon provokes MES.. Gopractice patterns. It does though raise some important
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modification of CAS as well as better prediction of partic-
ular events leading to ischemic cerebral lesions.
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Dr Brajesh Lal (Newark, NJ). I think this is an important area
of research, and we need to do this kind of research if we want to
improve the outcome of carotid stenting. With filter pore sizes
ranging from 80 to 150 microns, it is no surprise that some
microparticles will escape capture during carotid stenting. Our
group and several others have been reporting on this phenomenon
for at least the past 4 years.
The key assumption of your study is that transcranial Doppler
(TCD)-detected emboli are a faithful and accurate marker for risk
for stroke. You are using TCD-detected microemboli as a surro-
gate marker for risk for stroke. And because of that assumption,
there are several questions that need to be addressed before we can
accept that at face value. The true significance of these microem-
boli still remains elusive. Some studies have shown a correlation
between the number of emboli and the extent of microinfarction,
but others have not. Furthermore, some studies have shown a
correlation between the extent of microinfarction and the inci-
dence of stroke, while others have not. There are studies that have
tried to address this issue with completely conflicting results. I am
sure you are aware of that. So how do you try to reconcile your
results with what is in the literature in terms of the value of
TCD-detected microemboli and magnetic resonance (MR)-
detected microinfarctions with clinical outcomes?
The second question is along similar lines. The Pittsburgh
group has reported on perhaps the only randomized trial of carotid
stenting with and without a filter that showed no difference in
stroke rates or computed tomography (CT)-measured microin-
farcts in the two groups. In fact, the infarct numbers were higher in
the elderly patients with a filter compared with patients that did not
have a filter. How do you reconcile that with your findings?
Third question, if the microemboli do not serve as markers for
risk for stroke, then can they be predictors or markers for some-
thing else? We are very interested in cognitive function and we are
currently in the process of completing an American Heart Associ-
ation (AHA) -sponsored study, looking at cognitive outcomes and
microemboli counts. So I would like your comments on that, too.
Fourth, a question on methodology. How practical do you
think TCDmonitoring is for every carotid stenting case, especially
with the submandibular probe, which can, as I have observed, get
in the way of good imaging. It is a fairly crowded, small field.
Would you recommend this for all procedures, or limit it to an
investigative tool where you could assess the performance of one
filter versus the other?
Dr Jean Bismuth. We had a discussion earlier about diffusion-
weighted images (DWI) and its importance. I think, as you men-cance of these lesions is. We did not use DWI in our patients. But
there is one study that I briefly mentioned in the beginning, which
is just out, and it does show that a lot of these lesions out
approximately a month do reverse. I think with stents what hap-
pens is you have a cumulative effect, and I think that what is going
to be important is that you have continued microembolization,
and possibly TCD could play a role in evaluating these patients and
seeing whether patients with these stents, long term, have contin-
ued microembolization. And that may give you the potential to
predict poor outcome a little bit better.
Simultaneous pre- and postfilter TCD monitoring is a good
tool to evaluate our protection devices and see what works and
should primarily be used in that role. I think TCD has a role during
stenting, not only for embolization, but changes in flow patterns
due to complications are almost immediate, thereby allowing you
to react a little sooner than you can possibly with electroencepha-
logram (EEG).
Dr Alipour I just want to make one comment. I would
strongly urge you to review some of the literature on especially the
two most recent randomized trials in cardiothoracic surgery where
aortic filters were used and TCD-detected microemboli were vir-
tually eliminated, but the incidence of cognitive dysfunction did
not change. So there is a lot more we need to understand about
these three things before we can come to some clinical conclusion.
Dr Bismuth. For your first comment, there are actually
several studies out showing that the plaque characteristics do not
necessarily predict outcome. One would expect poorer outcomes
when treating vulnerable plaques, but that is not really the case.
Dr Alipour. Not the outcome, but the shower of emboli is
more common.
Dr Bismuth. Sure.
Dr Wei Zhou (Stanford, Calif). It appears that TCD is an
excellent method examining real-time microemboli during carotid
stenting.We have also evaluatedmicroembolic phenomenon using
DW-magnetic resonance imaging (MRI) over the last several years.
Studies have shown that microemboli may occur 48 hours after the
stenting procedures. Have you or are you planning to perform
postprocedural TCD? Although we do not know the cognitive
effects of microemboli yet, it will be important to know what
percentage of microemboli occurs after stenting.
Dr Bismuth.We have not looked at that data, so I would not
be able to tell you. I can tell you that we are now, as a standard,
preoperatively doing TCD and, obviously, carotid duplex, and
following that postoperatively. So hopefully in the next year or so,tioned, the literature varies quite a bit on what exactly the signifi- we should be able to give you some numbers on that.
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JOURNAL OF VASCULAR SURGERY
February 2009345.e1 Garami et alFig 2, online only. Schematic representation of normal transcranial Doppler (TCD) signals from a transtemporal
probe placement. Middle cerebral artery (MCA) (red: 40-60 mm), anterior cerebral artery (ACA) (blue: 60-70 mm),
and contralateral ACA (red: 70-80 mm) (Schematic drawing courtesy of Debra Liles Canter.)
Fig 3, online only. Channel 1: Submandibular internal carotid artery (SICA) recording two microembolic signals
(MES) (orange arrows). First one on the channel 2 power M-mode Doppler screen (recoding middle and anterior
cerebral artery [MCA  ACA]) traveled to ACA (white arrow). Second MES from SICA traveled to MCA (yellow
arrow).
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 2 Garami et al 345.e2Fig 4, online only. Contrast injection is shown as hyperintense
signals on the PMD-TCD screen channel 1, in the middle anterior
cerebral artery (MCA), during four cardiac cycles and channel 2, in
the submandibular internal carotid artery (SICA), during seven
cardiac cycles.Fig 5, online only. On transcranial Doppler (TCD) monitor a
microembolic signals (MES) recorded on channel 1 in the sub-
mandibular internal carotid artery (SICA) is seen after a delay of a
single heartbeat in the middle anterior cerebral artery (MCA) by
transtemporal transcranial Doppler (TCD) probe on the lower
channel 2.
